Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT02954094
Active, not recruiting Observational

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT02954094 · tracked via the Priya Life Science Spain tracker
Sponsor
Target PharmaSolutions, Inc
Phase
Observational
Started
2016-12
Last updated
2026-04-17

Condition(s) studied

Hepatocellular Cancer

Study summary

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Male or female patients, age ≥18 years 2. Patients with a histological/cytological or radiological diagnosis of HCC (mixed HCC cholangiocarcinoma may be included; patients who are candidates for surgical and non-surgical treatment, as well as those being followed without specific HCC therapy may be included) Exclusion Criteria: 1\. Inability to provide written informed consent

Primary outcome measure(s)

  • Establish a longitudinal observational cohort to understand the natural history and management of HCC, including the safety and outcomes of HCC treatment interventions utilized in usual clinical practice — Up to 15 years

Trial sites (71)

FacilityCityRegionStatus
Banner University Medical Center Phoenix Arizona
University of Arkansas Little Rock Arkansas
University of Southern California/Norris Comprehensive Cancer Center Los Angeles California
Stanford University Palo Alto California
California Liver Research Institute Pasadena California
University of California-Davis Sacramento California
University of California San Francisco California
Georgetown University Washington D.C. District of Columbia
Gastro Florida Clearwater Florida
University of Florida Hepatology Research at CTRB Gainesville Florida
University of Florida Health Gastroenterology Jacksonville Florida
Schiff Center for Liver Diseases/University of Miami Miami Florida
Tampa General Medical Group Tampa Florida
Piedmont Atlanta Hospital Atlanta Georgia
Piedmont Cancer Institute Atlanta Georgia
Emory University Hospital Atlanta Georgia
Northwestern University Division of Gastroenterology and Hepatology Chicago Illinois
Rush University Medical Center Chicago Illinois
University of Chicago Chicago Illinois
University of Iowa Hospitals and Clinics Iowa City Iowa
Tulane University New Orleans Louisiana
Mercy Medical Center, GI Research Baltimore Maryland
Johns Hopkins University Baltimore Maryland
Beth Israel Deaconess Medical Center Boston Massachusetts
University of Michigan Ann Arbor Michigan
Henry Ford Health System Detroit Michigan
Mayo Clinic Rochester Minnesota
Southern Therapy and Advanced Research (STAR) LLC Jackson Mississippi
Saint Louis University St Louis Missouri
University of Nebraska Medical Center Omaha Nebraska
Rutgers-Robert Wood Johnson Medical School New Brunswick New Jersey
Northwell Health - Center for Liver Diseases Manhasset New York
NYU Langone Health New York New York
Weill Cornell Medical College New York New York
Columbia University New York New York
University of North Carolina at Chapel Hill Chapel Hill North Carolina
Center for Liver Disease and Transplant at CMC Charlotte North Carolina
Providence Health & Services Cancer Clinical Trials Portland Oregon
Penn State Hershey Medical Center Hershey Pennsylvania
University of Pennsylvania Philadelphia Pennsylvania

+ 31 more sites — see the full list on the official registry below.

More Target PharmaSolutions, Inc. trials in Spain

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC Active, not recruiting

Other trials for the same condition

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02954094 on ClinicalTrials.gov ↗ ← All trials in Spain